Home・Lista de Ações・Insmed

Insmed

Fechado

SetorSaúde

98.72 0.46

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

96.22

Máximo

99.38

Indicadores-chave
By Trading Economics
Rendimento	165M -164M
Vendas	42M 306M
EPS	-0.76
Margem de lucro	-53.458
Funcionários	1,664
EBITDA	164M -136M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+100.98% upside

Dividendos
By Acuity
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-7.5B 23B
Abertura anterior	98.26
Fecho anterior	98.72

Sentimento de Notícias

By Acuity

43%

57%

135 / 340 Ranking em Healthcare

Insmed Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 19:16 UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

31 de jul. de 2026, 20:06 UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 de jul. de 2026, 21:16 UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

28 de jul. de 2026, 19:26 UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

27 de jul. de 2026, 23:41 UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

24 de jul. de 2026, 23:46 UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

22 de jul. de 2026, 19:11 UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

21 de jul. de 2026, 17:41 UTC

Social Media

News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

20 de jul. de 2026, 19:16 UTC

News

Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Comparação entre Pares

Variação de preço

Insmed Previsão

Preço-alvo

By TipRanks

100.98% parte superior

Previsão para 12 meses

Média 198.17 USD 100.98%

Máximo 243 USD

Mínimo 160 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Insmed - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

Comprar

Manter

Vender

Com base em 20 analistas que deram avaliações de ações para Insmed - Dist nos últimos 3 meses.

Sentimento

By Acuity

135 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.